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Ovarian cancer is responsible for the largest
proportion of deaths among patients with gynecologic
cancer. This paper discusses fluorodeoxyglucose positron
emission tomography/computed tomography (FDG
PET/CT) in the imaging of ovarian cancer. We discuss and
demonstrate how FDG PET/CT can be used to
appropriately guide clinical management decisions in
patients with ovarian cancer. In particular, FDG PET/CT
shows great promise for the preoperative evaluation of
women with primary ovarian cancer and for subsequent
postoperative assessment for recurrence.
2. INTRODUCTION
The American College of Radiology guidelines
state that the goals of oncologic imaging with PET/CT are
to help discriminate benign from malignant disease,
quantify the extent of malignant disease, detect residual
and recurrent disease and to monitor and guide therapy
(1). To date, ultrasound and computed tomography
(CT), have been the mainstay of imaging evaluation of
patients with ovarian cancer. The optimal role for
fluorodeoxyglucose positron emission tomography
(FDG PET) and PET/CT for the evaluation of ovarian
malignancy is being extensively studied. This paper
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reviews the current status of FDG PET/CT in the imaging
of ovarian cancer (2).
3. FDG PET/CT TECHNIQUE
At the authors’ institution, we perform PET/CT
examinations using a 64-slice multidetector CT (MDCT)
integrated with a PET system which uses 3D lutetium
oxyorthosilicate crystals. FDG is administered according to
patient body mass index (BMI). Adults with a BMI less
than 30 receive 15 mCi, patients with a BMI between 30
and 35 receive 20mCi and very obese patients receive 25
mCi. We require that patients fast for a minimum of 4
hours prior to imaging, and blood glucose is confirmed to
be less than 200 mg/dL before FDG administration.
Following FDG injection, patients are encouraged to drink
water and void regularly in order to minimize pelvic
irradiation and reduce normal bladder FDG activity at the
time of imaging. We do not routinely catheterize the
bladder prior to PET/CT in patients with ovarian cancer.
An attenuation correction CT is acquired from the skull
base to mid-thigh in order to facilitate FDG localization
and calculate attenuation correction to be applied to PET
images. This attenuation correction CT is usually acquired
one hour after FDG administration. PET images are then
immediately acquired from skull base to mid thigh and
these images are fused with the contemporaneous
diagnostic quality contrast-enhanced, neck, chest, and
abdominal CT examination which is usually performed
with intravenous administration of 120 mL of iodinated
contrast medium (iopamidol 370 mg [Iopamiro, Bracco
Diagnostics]). Our interpretation of the subsequent imaging
is performed by three attending radiologists; a chest
radiologist, an abdominal radiologist and a nuclear
medicine radiologist. Each radiologist studies both the
attenuation corrected PET images and the diagnostic CT
images. The fused PET/CT is mainly used for visual
interpretation and tumor volume measurements. Once the
imaging has been independently studied, the three
radiologists review the imaging together and arrive at a
consensus prior to issuing a report of their interpretations.
Final interpretation should bear in mind the following
response patterns: Persistent disease is disease which has
demonstrated a partial response to initial therapy and then
an immediate elevation of CA125 or clinical evidence of
disease. Chemotherapy resistant disease refers to
recurrence detected within 6 months of completion of
initial treatment. Refractory/Unresponsive/Progressive
disease refers to progression during initial therapy.
Recurrent ovarian cancer refers to recurrence after
complete initial response to first line therapy, negative
second look operation and a disease free interval of greater
than 6 months.
4. FDG PET/CT IMAGING APPEARANCES
4.1. Distinguishing physiologic from pathologic
increased ovarian FDG uptake,
Ovarian FDG uptake varies during differing
phases of the menstrual cycle in premenopausal women
which can lead to diagnostic uncertainty; however, there
are a number of helpful indicators of non-significant FDG
uptake that can be sought. Physiologic ovarian FDG uptake
is particularly pronounced in the early luteal phase (Figure
1). Normal physiological ovarian FDG uptake can be
minimized by imaging immediately following
menstruation. PET/CT is rarely deliberately timed so as to
be performed at the beginning of the menstrual period in
the authors’ institution. Occasionally PET/CT may be so
performed in selected cases where there is known
malignancy in the pelvis and it is believed that
physiological ovarian uptake would compromise image
interpretation. Typically, physiologic ovarian FDG uptake
shows spherical or discoid-shaped uptake with smooth
margins. Normal ovarian uptake is usually located above
the urinary bladder or around the uterus. Combined
PET/CT offers advantages over PET alone in this
circumstance as the features of normal ovarian uptake on
PET can be correlated with the CT component of the exam
in order to help distinguish physiological from pathologic
uptake. Normal benign ovarian tissue can have
characteristic small rim-enhancing cysts on CT, there
should be no regional lymphadenopathy, and there should
be concordance with the appropriate stage of the menstrual
cycle (3). Ovarian FDG uptake in a post menopausal
patient however should always be considered pathologic.
4.2. Distinguishing benign versus malignant lesions
Combined structural and metabolic data acquired
contiguously with PET/CT has facilitated more accurate
localization of suspicious areas of increased FDG uptake
and improved interpretation of unexpected findings in the
ovaries. While older studies which evaluated the use of
PET alone for the early diagnosis of ovarian cancer have
reported a disappointingly low sensitivity (58%) and
specificity (76%), combined PET/CT has demonstrated a
sensitivity of 87% and specificity of 100% for
differentiating benign from malignant ovarian cancer (4, 5).
These results were achieved when a focal increased
standardized uptake value (SUV) of 3 or higher in the ovary
was interpreted as indicative of ovarian malignancy, while
an SUV of 2.7 or less was considered benign. Benign and
malignant ovarian FDG uptake on PET were also
differentiated using information provided by the
contemporaneously acquired CT, such as the presence of
characteristic patterns of benign FDG uptake as described
in the preceding section and the absence of
lymphadenopathy in patients with benign lesions. Four
false-negative PET/CT studies were recorded. Three of the
four primary tumors which were PET/CT negative
measured 5 mm or less. While SUV values are not
routinely reported in the authors’ institution, the intensity
of FDG uptake is correlated with the morphology of the
lesion which it correlates with on CT, and an interpretation
of the significance of this uptake is then made.
Further research has demonstrated that PET/CT
has a sensitivity of 80% and a specificity of 97% for the
diagnosis of synchronous malignancy in the contralateral
ovary in patients with primary ovarian cancer (6). Even
though PET/CT is relatively specific for the assessment of
ovarian lesions that are greater than 5 mm in size, its
sensitivity is low compared with ultrasonography for the
assessment of small (<5mm) lesions although all current
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Figure 1. Transverse PET, intravenous contrast enhanced CT, and fused PET/CT images in a premenopausal woman with
physiologic uptake in a normal ovary. A, There is a spherical area of increased FDG uptake (arrow) in the right adnexal region on
PET. B, Morphologically normal right ovary (arrow) containing follicular and corpus luteum cysts as seen on CT. C, Fused
images confirms increased FDG uptake is within the ovary (arrow)
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Table 1. International federation of obstetric gynecology (FIGO) and TNM staging systems for ovarian cancer
Tumor Type, TNM
Category FIGO Stage Description
Primary tumor (T)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 I Tumor limited to ovaries (one or both)
T1a IA
Tumor limited to one ovary; capsule intact, no tumor on ovarian surface; no malignant cells in ascites or
peritoneal washing
T1b IB Tumor limited to both ovaries
T1c IC
Tumor limited to one or both ovaries with any of the following: capsule ruptured, tumor on ovarian
surface, malignant cells in ascites or peritoneal washings
T2 II Tumor involves one or both ovaries with pelvic extension or implants
T2a IIA Extension or implants on uterus or tube(s); no malignant cells in ascites or peritoneal washings
T2b IIB Extension to or implants on other pelvic tissues; no malignant cells in ascites or peritoneal washings
T2c IIC Pelvic extension or implants (T2a or T2b) with malignant cells in ascites or peritoneal washings
T3 III
Tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside the
pelvis
T3a IIIA Microscopic peritoneal metastasis beyond pelvis (no macroscopic tumor)
T3b IIIB
Macroscopic peritoneal metastasis bey ond pelvis 2 cm in greatest dimension
T3c IIIC Peritoneal metastasis beyond pelvis > 2 cm in greatest dimension or regional lymph node metastasis
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 IIIC Regional lymph node metastasis
Distant metastasis (M)
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1
IV
Distant metastasis (excludes peritoneal metastasis)
Table 2. Summary of TNM and international federation of obstetrics gynecology staging of ovarian cancer
Stage Grouping Primary Tumor Stage (T) Regional Lymph Node Stage (N) Distant Metastasis Stage (M)
I T1 N0 M0
IA T1a N0 M0
IB T1b N0 M0
IC T1c N0 M0
II T2 N0 M0
IIA T2a N0 M0
IIB T2b N0 M0
IIC T2c N0 M0
III T3 N0 M0
IIIA T3a N0 M0
IIIB T3b N0 M0
IIIC T3c N0 M0
Any T N1 M0
IV Any T Any N M1
imaging modalities are limited in accurately characterizing
such small lesions.. In addition, the majority of patients
which are screened for ovarian disease with ultrasound do
not have malignancy and for the vast majority of these
patients PET/CT would be wasteful of a valuable resource
and impart unnecessary radiation exposure. Therefore, it is
the authors’ opinion that PET/CT should not replace
sonography for the screening of ovarian cancer. Given its
high specificity, FDG PET/CT is more appropriately used
to assess for occult metastases for staging purposes or prior
to surgical intervention.
5. STAGING OF OVARIAN CANCER
Ovarian cancer is surgically staged in accordance
with the International Federation of Gynecology and
Obstetrics TNM staging system (7) (Tables 1 and 2). Stage
I cancer is limited to the ovaries, stage II to the pelvis, stage
III beyond the pelvis and stage IV involves distant sites
such as the liver parenchyma. Nodal spread can occur
through the gonadal lymphatics to the retroperitoneum, via
the broad ligaments to the obturator, internal and external
iliac nodes, and via the round ligaments to the inguinal
nodes. Peritoneal spread follows the route of normal
peritoneal fluid circulation and occurs in areas of relative
stasis such as at the rectosigmoid junction, paracolic gutters
and beneath the right hemidiaphragm (8). Traditionally, CT
has been the preferred imaging modality for primary
preoperative staging of ovarian cancer. Combined PET/CT
has been shown by recent studies to be beneficial in
evaluating distant metastases and equivocal lesions (5, 6).
For example, in one study, CT alone incorrectly under-
staged four of six patients with stage four ovarian cancer
because distant metastases were not identified (5). PET/CT
was highly sensitive for peritoneal deposits which exceeded
1 cm in diameter and lymph nodes exceeding 7 mm.
PET/CT has been reported to increase pretreatment staging
accuracy compared with CT alone from 53–55% to 69–
75% (Figure 2 and 3) (5). The sensitivity of PET/CT is
limited for the detection of varieties of ovarian cancer with
poor FDG uptake such as mucinous tumors and for the
assessment of lymph nodes less than 7mm in size and
peritoneal deposits less than 1cm (9). It has been suggested
that one of the most helpful aspects of information that
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Figure 2. Transverse PET, intravenous contrast enhanced CT, and fused PET/CT images in a 73-year-old post menopausal
woman with Leydig cell ovarian cancer. A, There is a focus of intense FDG uptake in the right adnexal region on PET (arrow).B,
There is an abnormal soft tissue lesion on CT posterior to the right external iliac artery and vein (arrow). C, Fused images help
localize the increased FDG uptake to the soft tissue nodule (arrow). This information was of assistance to the surgeon at
subsequent diagnostic laparoscopy where tissue was obtained and the diagnosis of ovarian cancer was made.
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Figure 3. Transverse PET, intravenous contrast enhanced CT, and fused PET/CT images in a 63-year-old post menopausal
woman with ovarian cancer and extensive peritoneal metastases.A, There are crescent-shaped areas of FDG uptake on the small
bowel mesentery on PET (arrow). B, There is abnormal soft tissue in the omentum on CT (arrow) with associated ascites
(arrowhead) and inflammatory fat stranding. Due to the close proximity between bowel, fat standing and peritoneal disease, the
soft tissue planes are indistinct and the tumor extent is uncertain on CT alone. C, Fused images help localize the local extent of
tumor (arrow) within the abdomen. Note the increased uptake in the peritoneum surrounding the liver (arrowhead). Findings are
important for assessment of tumor burden and for oncological follow-up in this case which is not amenable to surgical cure.
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PET/CT provides is that it helps distinguish between
stage I–IIIB cancer from stage III C–IV cancer. This
distinction is very important since optimal treatment
for stage 1-111B disease entails debulking surgery
whereas, the majority of patients with stage IIIC-IV
disease are better treated with chemotherapy. PET/CT
for the purpose of making this vital distinction has a
specificity, sensitivity, and accuracy of 91%, 100%,
and 98%, respectively, compared with 64%, 97%, and
88% for CT (6). This has been recognized by the
European Society of Urogenital Radiologists (ESUR)
which has stated that PET/CT may be indicated when
there is suspected stage IV disease or where
intravenous contrast is contraindicated, although the
Society believes that the benefits of PET/CT over CT
for the staging of ovarian cancer have not been clearly
established (10).
6. DETECTION OF RECURRENT DISEASE
Approximately 75% of patients with ovarian
cancer experience disease recurrence following
treatment with curative intent (11). Early diagnosis and
accurate localization of recurrence and of metastases are
essential for appropriate clinical decision-making. This
is because the number of sites of recurrence affects
prognosis following cytoreductive surgery for recurrent
ovarian cancer (12). PET/CT is particularly valuable in
this setting for the detection of disease that could
otherwise be missed on CT such as peritoneal disease.
Peritoneal deposits in the greater omentum, on the
diaphragm or on the surface of the liver can sometimes
be easily overlooked on CT alone. Ascites is a less
common feature of recurrent ovarian cancer compared
with primary cancer and its presence is suggestive of
widespread peritoneal disease (10). The serological
tumor marker CA-125 has a high sensitivity for early
detection of recurrence, however, it does not quantify
tumor burden or indicate the location of recurrence. CA-
125 also has a poor negative predictive value (13).  PET
has a sensitivity of 96% for the detection of recurrent
disease when CA-125 levels rise and reportedly predates
CT appearances by six months (14). The ESUR
acknowledges the growing data in support of the role for
PET/CT when CA-125 is increasing but where
conventional imaging is inconclusive and that PET/CT
has a role when there is suspicion for recurrence and CT
and MRI are negative (10). CT has been the standard
imaging technique for evaluation of suspected
recurrence of ovarian cancer. Accuracy of CT varies
from 38% to 88% (15). PET/CT has been shown to
increase the accuracy of diagnosing recurrence (Figures
4, 5 and 6). FDG PET/CT is considered appropriate by
the American College of Radiology for the imaging of
patients with suspected recurrence and a negative CT
and for the assessment of patients with oligometastatic
disease on CT as part of treatment planning (16). The
patient-based sensitivity, specificity, and accuracy of
PET/CT ranges from 53% to 97%, 80% to 97%, and
68% to 92%, respectively (15, 17-18). The lowest
sensitivity of 53% was reported in a study where the
lesions which were FDG negative measured less than 5 mm
in size; below the resolution of PET/CT and essentially all
other currently available imaging techniques (15).
PET/CT has a high positive predictive value of 89%–
98% for recurrence of ovarian cancer and appears to
be more sensitive for the detection of extra-pelvic
lesions than for pelvic lesions (19). This is partly
because physiologic bladder uptake can obscure
pathologic pelvic uptake. Additionally, the erroneous
interpretation of FDG uptake due to postsurgical
pelvic inflammatory changes as representative of
tumor recurrence can lead to false-positive results on
PET/CT.
The profile of PET/CT for restaging
recurrent ovarian cancer has been raised due to its
ability to help physicians accurately localize lesions
and quantify the extent of recurrence and metastases.
PET/CT for the prediction of optimal cytoreduction
in recurrent ovarian cancer has a reported accuracy of
79%, sensitivity of 93%, specificity of 56%, positive
predictive value of 77%, and negative predictive
value of 83% (20). Therefore FDG PET/CT has good
efficacy in planning surgical treatment of patients
with recurrent ovarian cancer (20). PET/CT was
found to be comparable to staging laparoscopy for
this purpose with the caveat that false-negative
results are most likely to occur due to limited
detection of small peritoneal implants which measure
less than 7 mm in size. It has been shown that
information gained from PET/CT changes treatment
technique for 44-57% of patients (21, 22).
7. POTENTIAL LIMITATIONS
The accurate characterization of lesions that
measure less than 1cm in diameter using FDG
PET/CT is suboptimal due to the spatial resolution
limitations of PET. This has important implications
for the detection of small deposits of malignancy
such as miliary disease, for which a false-negative
rate of 5%–10% is quoted. Detection of small
peritoneal deposits measuring less than 5mm in size
is also limited due to significantly lower SUV values
(p=0.006) probably due to reduced FDG uptake and
spatial resolution limits of PET (23). The presence of
bowel peristalsis in the abdomen and pelvis combined
with physiological bowel and bladder uptake can
create misregistration of PET and CT data and
interfere with interpretation (24). Usually an
awareness of this phenomenon and careful image
review are sufficient for accurate interpretation.
PET/CT for the detection of recurrent ovarian cancer
can also be limited by the difficulty distinguishing
postoperative inflammatory changes from tumor
recurrence or persistence (Figure 7). Often,
correlation with prior imaging, clinical, and
biochemical examinations helps determine the
significance of abnormal FDG uptake and helps
decision making. The reporting radiologist should
also be aware of the potential for low FDG uptake
either by necrotic tumors or those which contain
considerable amounts of mucin (8).
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Figure 4. Transverse PET, intravenous contrast enhanced CT, and fused images in a 62-year-old-woman with metastatic ovarian
cancer to the liver. A, There is increased FDG uptake in the segment 4B of the liver (arrow) adjacent to the falciform ligament on
PET imaging.  B, A metastatic deposit in segment 4B is confirmed on CT (arrow).  C, Fused images confirms increased FDG
uptake in the liver lesion identified on CT (arrow). No other foci of abnormal increased uptake were seen within the liver.
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Figure 5. Transverse PET, intravenous contrast enhanced CT, and fused PET/CT images with bone windows in a 72-year-old-
woman with metastatic ovarian cancer to the retroperitoneum. A, There is a small focus of increased FDG uptake in the
retroperitoneum on PET (arrow). It is not possible to differentiate between normal ureteric or metastatic uptake based on PET
alone. A second focus of increased FDG uptake is seen in a vertebra at this level (arrowhead). B, On soft tissue windows, there is
a small linear soft tissue lesion posterior to the right ureter on CT (arrow).  C, On bone windows, it can be seen that there is
hypertrophy at the level of the facet joint (arrowhead).  D, Fused images confirm increased FDG uptake in the retroperitoneum
lies within the soft tissue lesion, likely a lymph node posterior to the right ureter (arrow) rather than in the ureter itself. This
uptake is therefore highly suspicious for metastatic disease. Increased spinal uptake is due to facet joint hypertrophy rather than
malignancy (arrowhead).
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Figure 6. Coronal PET, intravenous contrast enhanced CT, and fused axial PET/CT images in a 59-year-old-woman with
recurrent ovarian cancer in the pelvis previously treated with hysterectomy and bilateral salpingo-oophrectomy with a CA-125
level of 11,500. A, There is a discrete focus of avid FDG uptake in the pelvis on PET (arrows). Based on the PET images alone it
is difficult to accurately differentiate this uptake from normal bowel uptake, ureter or a bladder diverticulum. Incidental note is
made of increased FDG uptake in the upper right thigh (arrowhead). B, There is a soft tissue lesion in the pelvis on CT (arrow).
C, Fused images confirms increased FDG uptake in two soft tissue pelvic lesions rather than in bowel and therefore these
deposits are likely metastases (arrows). Upper right thigh FDG uptake is again noted (arrowhead) without a mass on CT. This
increased FDG uptake is due to muscle activity and not metastatic disease.
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Figure 7. Transverse PET, intravenous contrast enhanced CT, and fused PET/CT images in a 59-year-old-woman (same case as
in Figure 6) with recurrent ovarian cancer at site of previous surgery and CA-125 level of 11,500. A, There is abnormal FDG
uptake in the anterior abdominal wall on PET (arrow).  B, There is subtle increased soft tissue thickening in the region of the
surgical clips (arrow) in the anterior abdominal wall that could be secondary to surgery and represent suture granuloma or
fibrosis. C, Fused images confirm increased FDG uptake in the anterior abdominal wall at the level of the surgical clips (arrow).
The prior surgery was 2 years before the PET/CT and therefore this uptake is abnormal and highly suspicious for metastatic
disease.
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8. CONCLUSION
The American Cancer Society estimates that
ovarian cancer will account for 21,990 new malignancies
and 15,460 deaths in 2011 in the United States, which
makes ovarian cancer responsible for the greatest number
of deaths among patients with gynecologic malignancy (1).
FDG PET/CT is an important tool for the preoperative
evaluation and post operative surveillance of these women.
FDG PET/CT has the potential to provide clinically
important information and appropriately direct patient
management. Pending better data from randomized studies,
PET is currently best indicated for the staging of ovarian
cancer when stage IV disease is suspected or intravenous
contrast is contraindicated. In the setting of suspected
recurrent disease PET should be considered if conventional
imaging is inconclusive in the presence of rising CA-125
titers.
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